Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
The initiative was announced at World Hypertension Congress, Chennai
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Rising demands and advancements in eye care drive growth
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme
Subscribe To Our Newsletter & Stay Updated
